Morgan Stanley has lowered its price target on Recursion Pharmaceuticals (NASDAQ:RXRX) to $5 from $8, while maintaining an ...

“Small experiments with radical intent. That’s how we live our lives at Punchcard ,” says Jenkins, CEO of the Edmonton-based digital transformation studio, referencing advice he once received from an ...